13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details


Clinical trials : 3,342 Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04670770
(ClinicalTrials.gov)
December 24, 202010/12/2020An Open Label Study of the Effects of SHR1459 in NMOSDs PatientsAn Open Label Phase II Clinical Trial Evaluating the Efficacy and Safety of SHR1459 in Adult Patients With Neuromyelitis Optical Spectrum Disorders (NMOSDs)Neuromyelitis Optica Spectrum DisordersDrug: Drug - SHR1459Reistone Biopharma Company LimitedNULLActive, not recruiting18 Years75 YearsAll10Phase 2China